-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $300

Benzinga·10/28/2026 19:12:48
Listen to the news
JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $276 to $300.